Bedrijfsoverzicht
Unicycive Therapeutics, Inc. is a clinical-stage biotechnology entity dedicated to identifying, developing, and commercializing therapies aimed at addressing significant unmet medical needs within the United States healthcare landscape. The company operates specifically within the Healthcare sector, focusing on the Biotechnology industry, which involves high-risk, high-reward research and development cycles intended to bring novel drug candidates to market. As of the latest available data, the company holds a market capitalization of $167.33M and employs a workforce of 21 individuals, while reporting no disclosed annual revenue figures in the trailing twelve-month period. The current market capitalization of $167.33M suggests that the company is a micro-cap entity with a relatively small valuation compared to established pharmaceutical peers, reflecting the early-stage nature of its development pipeline and the inherent uncertainty associated with its primary asset, UNI 494. The absence of reported revenue further contextualizes the company's position as a pre-commercialization venture where value is derived entirely from intellectual property potential rather than current sales performance.
Financiële gezondheid
In terms of profitability metrics, Unicycive Therapeutics, Inc. reports a net income of $-26,555,000 for the trailing twelve months, with an EBITDA of $-29,483,000 and no disclosed revenue for the same period. The substantial negative net income relative to zero revenue indicates a cost structure dominated by research and development expenses and general administrative costs typical of clinical-stage biotechnology firms, where significant capital is expended before any product generates sales. The company generated free cash flow of $-22,924,500, which signifies a continuous burn rate that necessitates ongoing capital raising efforts to maintain financial flexibility and fund future clinical trials. Margin analysis reveals a gross margin of 0.0%, an operating margin of 0.0%, and a profit margin of 0.0%, all of which are expected for a company in the development phase that has not yet achieved commercial scale or cost of goods sold efficiency. The company maintains a cash balance of $41.27M against total debt of $117,000, resulting in a debt-to-equity ratio of 0.39, which demonstrates a highly conservative balance sheet with negligible leverage and minimal interest obligations. Liquidity is supported by a current ratio of 2.58, indicating that the company possesses 2.58 times more current assets than current liabilities, thereby ensuring a robust position to meet short-term obligations without immediate refinancing needs. Return on equity stands at -141.1% and return on assets is -45.7%, metrics that reflect the dilutive nature of current operations and the fact that management effectiveness is currently measured by the preservation of capital for future growth rather than the generation of shareholder returns from profits.
Waarderingsbeoordeling
The valuation profile of Unicycive Therapeutics, Inc. is characterized by a trailing P/E ratio of N/A due to negative earnings, while the forward P/E is listed at 0.77, a metric that implies the market anticipates a significant turnaround in earnings or is utilizing a non-standard calculation based on projected positive earnings that contrasts sharply with historical losses. The price-to-book ratio is 4.86, indicating that the market values the company's equity at nearly five times its book value, which reflects a premium assigned to the company's intellectual property, clinical pipeline, and future revenue potential rather than current tangible assets. Alternative valuation metrics such as the price-to-sales ratio of N/A and an EV/EBITDA of -4.28 further highlight the speculative nature of the investment, where valuation is disconnected from current cash flows and sales generation. The stock has exhibited significant price volatility over the past year, trading between a 52-week low of $3.71 and a 52-week high of $11.00. Relative to this established trading range, the current market price sits in a position that reflects the ongoing uncertainty of the clinical development process, requiring investors to assess risk based on the distance from the recent lows and highs. The beta value is 1.80, which indicates that the stock's price volatility is substantially higher than the broader market, moving 80% more aggressively than the market index during periods of increased volatility.
Growth & Income
Unicycive Therapeutics, Inc. reports no disclosed revenue growth year-over-year and no disclosed earnings growth year-over-year, as the company has not yet generated positive revenue streams or consistent earnings growth patterns associated with mature commercial products. The absence of revenue growth data precludes a direct comparison between earnings and revenue expansion rates, yet the negative earnings growth implied by the net income figures underscores the company's focus on capitalizing resources for development rather than scaling sales operations. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means that all available cash flow is reinvested back into the business to fund research, development, and clinical trials rather than being distributed to shareholders. This reinvestment strategy is standard for clinical-stage biotechnology companies, where the primary goal is to advance drug candidates like UNI 494 through regulatory hurdles to achieve commercial viability, rather than providing immediate income to investors. The overall growth and income profile is defined by a complete reliance on capital appreciation potential and the successful execution of the clinical pipeline, offering no current income stream and presenting growth risks tied to the high probability of attrition in early-stage drug development.